Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Workday
WDAY
5
Enerpac Tool
EPAC
US Stock MarketDetailed Quotes
GRI GRI Bio
- 1.840
- +0.390+26.90%
Close Apr 23 16:00 ET
- 1.760
- -0.080-4.35%
Pre 08:02 ET
3.52MMarket Cap-0.03P/E (TTM)
2.110High1.510Low1.32MVolume1.510Open1.450Pre Close2.49MTurnover69.04%Turnover RatioLossP/E (Static)1.91MShares106.03652wk High0.87P/B3.52MFloat Cap1.10052wk Low--Dividend TTM1.91MShs Float480807.600Historical High--Div YieldTTM41.38%Amplitude1.100Historical Low1.880Avg Price1Lot Size
About GRI Bio Company
GRI Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapies for inflammatory, fibrotic, and autoimmune diseases. It focuses on its lead program, GRI-0621, an inhibitor of type 1 invariant Natural Killer T (iNKT) cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis. The company was founded by Vipin Kumar Chaturvedi in May 2009 and is headquartered in La Jolla, CA.
Company Profile
SymbolGRI
Company NameGRI Bio
Listing DateFeb 10, 2021
Founded2009
CEODr. W. Marc Hertz, PhD
MarketNASDAQ
Employees4
Fiscal Year Ends12-31
Address2223 Avenida De La Playa,Suite 208
CityLa Jolla
ProvinceCalifornia
CountryUnited States of America
Zip Code92037
Phone1-619-400-1170
Websitehttp://www.gribio.com
Company Executives
- Name
- Position
- Salary
- Dr. W. Marc Hertz, PhD
- President, Chief Executive Officer and Director
- 617.22K
- Leanne M. Kelly
- Chief Financial Officer and Principal Accounting Officer
- 469.42K
- Dr. Vipin Kumar Chaturvedi, PhD
- Chief Scientific Officer
- 419.42K
- Dr. Albert Agro, PhD
- Chief Medical Officer
- --
- David Szekeres
- Chairman of the Board
- 91.00K
- David Baker
- Director
- 40.00K
- Camilla V. Simpson, M.Sc.
- Independent Director
- 64.50K
- Roelof Rongen
- Independent Director
- 57.50K
Market Insights
Discussing
2025 Buffett shareholders' meeting: What's the new buzz in value investing?
🎙️Discussion 1. In the face of market changes, do you prefer to stick with growth stocks or switch to value stocks? 2. Based on the current
Moomoo News Global
Apr 9 20:29
Learning From Buffett: Investing Wisely Amid Market Volatility Triggered by Trump's Tariffs
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
Unlock Now
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Unlock Now
